ESMO IO 2022 – Luca Mazzarella
Luca Mazzarella discusses the effects of modifying the pharmacology of anti-PD1 agents on their efficacy/toxicity in patients with advanced squamous NSCLC, explains potential therapeutic benefits of adding anti-CTLA4 or de-escalating chemotherapy to anti-PD1 blockade and highlights the role of individual or combined predictive biomarkers and biostatistics tools.
Here is the full ESMO IO 2022 Solid Tumors report.
More posts
Emerging therapies in solid tumors
Emerging therapies in solid tumors BMS-986253 plus nivolumab and ipilimumab Interleuki
New strategies with PD-1/PD-L1 blockade in lung cancer
New strategies with PD-1/PD-L1 blockade in lung cancer Small-cell lung cancer (SCLC) ac
Preface – ESMO IO 2022
Preface - ESMO IO 2022 Matteo Simonelli, MD, Department of Biomedical Sciences, Humani
